Coronavirus Notebook: Leading Vaccines Near Approval, EU Signs More Advance Purchase Deals
Developers Are Under Pressure To Share Their IP And Reveal Costs
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
